Melphalan
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Melphalan: From Multiple Myeloma to Gonadal Germ Cell Tumour
One-Sentence Summary
Melphalan is a bifunctional alkylating agent, historically used for multiple myeloma and high-dose conditioning before autologous stem cell transplant. The TxGNN model predicts it may be effective for Gonadal Germ Cell Tumour, with 8 clinical trials and 4 publications currently supporting this direction. Note: no UK/Taiwan marketing authorisation records or formal SmPC warning data were available in this evidence pack (see Safety Considerations).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack (no licences on file). Melphalan is generally known as an alkylating chemotherapy agent used for multiple myeloma and, historically, ovarian carcinoma/high-dose ASCT conditioning — this is general pharmacological knowledge, not sourced from the pack. |
| Predicted New Indication | Gonadal Germ Cell Tumour |
| TxGNN Prediction Score | 99.77% |
| Evidence Level | L3 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed DrugBank mechanism-of-action data is flagged as a data gap in this pack. However, the evidence pack’s own repurposing rationale describes Melphalan as a bifunctional alkylating agent that induces DNA cross-linking, driving apoptosis preferentially in highly proliferative cells. Gonadal germ cell tumours (seminomatous and non-seminomatous) are classically among the most chemosensitive solid tumours to alkylating and platinum-based agents.
High-dose melphalan combined with autologous stem cell rescue is already established clinical practice as salvage therapy for relapsed/refractory germ cell tumours, giving this prediction a plausible mechanistic and practical basis rather than being a purely theoretical model output. The drug’s use in this context also has a long history — dating back to “sarcolysin” studies on testicular seminoma in the 1950s, as reflected in the literature evidence below.
Because gonadal GCTs are highly sensitive to DNA-damaging agents and melphalan’s dose-intensification/ASCT-rescue paradigm is already used off-label in this setting, the TxGNN prediction aligns with existing (if limited) clinical experience rather than contradicting it.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT00936936 | Phase 2 | Completed | 64 | Two cycles of high-dose chemotherapy (incl. melphalan) for poor-prognosis relapsed germ-cell tumours — most direct evidence for this indication. |
| NCT00003425 | Phase 1/2 | Completed | 25 | Escalating-dose melphalan with autologous stem cell support and amifostine cytoprotection; directly evaluates melphalan dose-response. |
| NCT00638898 | Phase 1 | Completed | 25 | Busulfan/melphalan/topotecan high-dose conditioning before autologous HSCT in advanced/recurrent tumours (incl. GCT). |
| NCT01272817 | N/A | Completed | 36 | Nonmyeloablative allogeneic HSCT using melphalan/cladribine or TLI conditioning across various malignancies. |
| NCT00003926 | Phase 1 | Terminated | 13 | Amifostine chemoprotection with autologous stem cell transplant for high-risk/relapsed paediatric solid and brain tumours. |
| NCT00536601 | N/A | Completed | 174 | Autologous blood/marrow transplantation regimens (with/without TBI) for haematologic and selected solid tumours. |
| NCT00060255 | Phase 2 | Completed | 451 | Large registry-style Phase 2 study of eight high-dose chemotherapy/ASCT regimens across haematologic and solid tumours. |
| NCT00002750 | Phase 1 | Completed | 6 | Intrathecal melphalan for recurrent neoplastic meningitis — indirect relevance only. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 24913 | 1977 | Review | The Urologic Clinics of North America | Review of seminoma management, including chemotherapy approaches. |
| 4270380 | 1973 | Review | Oncology | Review of chemotherapy for testicular germinal tumours. |
| 13392619 | 1956 | Case series | Voprosy Onkologii | Early clinical experience treating testicular seminoma and metastases with sarcolysin (an early melphalan formulation). |
| 14151951 | 1964 | Mechanistic/basic study | Acta Unio Internationalis Contra Cancrum | Investigates effects of hormonal and alkylating drugs on pituitary follicle-stimulating function. |
UK Market Information
No UK marketing authorisations are recorded for Melphalan in this evidence pack (market status: Not marketed; 0 licences on file). Prescribers should check the current MHRA product register and BNF entry directly, as Melphalan (e.g. Alkeran) has authorised uses elsewhere that are not reflected in this dataset.
Cytotoxicity
Melphalan is a conventional cytotoxic alkylating agent and this section applies.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (nitrogen mustard/alkylating agent, DNA cross-linker) |
| Myelosuppression Risk | High — inferred from the evidence pack, where nearly all identified trials pair melphalan with autologous or allogeneic stem cell rescue, indicating myeloablative or near-myeloablative dosing in practice |
| Emetogenicity Classification | Moderate to High, dose-dependent (high-dose IV regimens used with stem cell rescue are highly emetogenic) |
| Monitoring Items | FBC with differential, renal function, hepatic function; closer monitoring required at high-dose/ASCT-conditioning regimens |
| Handling Protection | Must follow cytotoxic drug handling regulations (preparation, administration, and waste disposal per local hazardous drug protocols) |
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: This evidence pack flags TFDA label warnings/contraindications as a Blocking data gap (DG001) — no key warnings, contraindications, or drug interaction data could be retrieved. This must be resolved before any formal S1 safety assessment can proceed.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The mechanistic rationale is plausible and supported by one directly relevant Phase 2 trial (NCT00936936) and a Phase 1/2 dose-finding study (NCT00003425), alongside decades-old but consistent literature on alkylating-agent sensitivity in germ cell tumours. However, evidence is observational/small-scale rather than confirmatory RCT-level (L3), and a Blocking safety data gap prevents a full risk assessment.
To proceed, the following is needed:
- Resolve DG001 (Blocking): obtain SmPC/product label warnings and contraindications, e.g. via MHRA/manufacturer SmPC, since this drug is not currently marketed in this jurisdiction
- Resolve DG002 (High): confirm formal DrugBank mechanism-of-action record to support the mechanistic rationale beyond the narrative description
- Formal DDI screening, as none was found in this pack
- Consider a targeted literature search restricted to modern (post-1990) high-dose melphalan/ASCT outcomes in relapsed germ cell tumours, as current literature evidence predates modern treatment standards
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.